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MuSiC: Identifying mutational significance
in cancer genomes
Nathan D. Dees,1,4 Qunyuan Zhang,1,4 Cyriac Kandoth,1 Michael C. Wendl,1,2
William Schierding,1 Daniel C. Koboldt,1 Thomas B. Mooney,1 Matthew B. Callaway,1
David Dooling,1 Elaine R. Mardis,1,2,3 Richard K. Wilson,1,2,3 and Li Ding1,2,5
1The Genome Institute, Washington University, St. Louis, Missouri 63108, USA; 2Department of Genetics, Washington University,
St. Louis, Missouri 63110, USA; 3Siteman Cancer Center, Washington University, St. Louis, Missouri 63110, USA
Massively parallel sequencing technology and the associated rapidly decreasing sequencing costs have enabled systemic
analyses of somatic mutations in large cohorts of cancer cases. Here we introduce a comprehensive mutational analysis
pipeline that uses standardized sequence-based inputs along with multiple types of clinical data to establish correlations
among mutation sites, affected genes and pathways, and to ultimately separate the commonly abundant passenger
mutations from the truly significant events. In other words, we aim to determine the Mutational Significance in Cancer
(MuSiC) for these large data sets. The integration of analytical operations in the MuSiC framework is widely applicable to
a broad set of tumor types and offers the benefits of automation as well as standardization. Herein, we describe the
computational structure and statistical underpinnings of the MuSiC pipeline and demonstrate its performance using 316
ovarian cancer samples from the TCGA ovarian cancer project. MuSiC correctly confirms many expected results, and
identifies several potentially novel avenues for discovery.
[Supplemental material is available for this article.]
The continued advancement of DNA sequencing technologies
(Mardis 2011) now allows for the rapid sequencing of large sets of
cancer cases (matched tumor andnormal samples) for the purposes
of mutation discovery. This technological progression has shifted
the emphasis in cancer genomics from the analysis of a single pa-
tient sample to that of hundreds of patient samples across a broad
range of tumor types. Such an expansion of scope facilitates the
ascertainment of recurrent mutations within genes and functional
pathways. Additionally, the increasing scope permits correlating
mutations and pathways with clinical phenotypes where appro-
priate clinical data exist. The outcome of such correlation can in-
clude the identification of prognostic or diagnostic markers or the
identification of actionable targets for developing therapeutic
options that may inform clinical trials development.
To this end, we present a packaged suite of comprehensive,
user-friendly tools designed to determine mutational significance
in cancer (MuSiC). The primary goal of MuSiC is to separate the
significant events which are likely drivers for disease from the
passenger mutations present in mutational discovery sets using
a variety of statistical methods. This package provides unique prac-
tical advantages over existing software and requires a few basic
input elements: mapped reads in BAM format, predicted or val-
idated single nucleotide variants (SNVs) and indels in mutation
annotation format (MAF), a set of regions of interest (typically the
boundaries of coding exons), and any relevant numeric and/or cat-
egorical clinical data. Usage is straightforward. With a single com-
mand, a user can (1) apply statistical methods across the cohort to
identify significantly mutated genes and (2) identify significantly
altered pathways and gene sets, (3) investigate the proximity of
amino acidmutations within the same gene, (4) search for gene-
based or site-based relationships and correlations between the
mutations themselves, (5) correlate mutations to clinical features,
and (6) cross-reference the findings with relevant databases, such
as Pfam (Finn et al. 2010), COSMIC (Forbes et al. 2008), andOMIM
(McKusick 1998). These functions can be accessed individually or
run as an automated serial implementation.
To illustrate performance, we tested the MuSiC suite on an
exome capture data set consisting of 316 cases of ovarian carci-
noma (OV) that were previously described by the TCGA Research
Network (The Cancer Genome Atlas Research Network 2011). The
original analysis provided statistically supported lists of signifi-
cantly mutated genes, therapeutically targetable copy number
amplifications in several genes (e.g.,MECOM,MAPK1,CCNE1, and
KRAS), evidence of overlaps between DNA methylation clusters
and gene expression subtypes, and confirmation of involvement
of the NOTCH and FOXM1 signaling pathways in serous ovarian
cancer pathophysiology.UsingMuSiC,we complement the previous
results with detailed descriptions of the correlations between muta-
tion spectra and clinical data. We found evidence of mutual exclu-
sion between mutations in two major tumor suppressors, TP53 and
RB1, and strong statistical support for the correlation of germline
BRCA1 point mutations and age at disease onset (Hall et al. 1990;
Miki et al. 1994). MuSiC also helps us confirm the importance of
mutations in the P53 DNA-binding domain (Sigal and Rotter 2000).
Results
Overview
The development of MuSiC was motivated by the rapidly
expanding numbers of mutation data sets from a wide variety of
tumor types. It is imperative during post-discovery analysis to
separate the significant, or ‘‘driver,’’ mutations from the passenger
mutations to more accurately pinpoint the key genes and pathways
4These authors contributed equally to this work.
5Corresponding author
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critical for disease initiation and progression. MuSiC is designed
precisely to streamline this process into an easily accessible high-
throughput software exercise.
MuSiC currently consists of seven analysis modules and an
eighth execution module, ‘‘MuSiC Play,’’ which runs each analysis
module sequentially (Fig. 1). MuSiC Play parses the input and out-
put of each of the individual modules and then produces a com-
posite summary of all executed modules. Table 1 lists the type of
analysis performed and the types of variants considered by each
individualMuSiCmodule.More detailed descriptions of the specific
analysis algorithms performed by each module are given below.
Significantly mutated gene tests
We use the concept of ‘‘significantly mutated genes’’ (SMG) to
describe genes that show a significantly higher mutation rate than
the background mutation rate (BMR) when multiple mutational
mechanisms (coding indel and single nucleotide substitution,
splice site mutation, etc.) are considered. Specialized measurements
of the BMR may also be considered; BMRs in MuSiC are optionally
calculated across the entire sample set, across particular subgroups
of similarly mutated samples, or for each sample individually. For
each BMR subgroup considered and for each category of mutational
mechanism, the mutation rates are compared to the appropriate
BMR, and a single P-value summarizing all considerations is gen-
erated for each gene. We refer to this summarization procedure as
the significantly mutated gene (SMG) test.
We assessed multiple methods of calculating summarized
P-values, including a convolution test (CT), a Fisher’s combined
P-value test (FCPT), and the likelihood ratio test (LRT), using
a partially simulated data set (this data set and the associated test
simulations are described in the Supplemental Material). By this
approach, we determined that the P-value distribution obtained
using the CT method most closely resembled the uniform distri-
bution expected under the null (in this case, the null is such that
no gene is truly significantly mutated), while the FCPT and LRT
methods produced slightly inflated or deflated P-values, respec-
tively (Supplemental Fig. S1). During the SMG test, a false discovery
rate (FDR) also is calculated. We evaluate our SMG test results by
establishing a P-value or FDR threshold (threshold typically 0.2 or
less for FDR), and then appropriately filtering the test output.
The results of MuSiC’s SMG analysis for the ovarian cancer
data set were previously reported (The Cancer Genome Atlas Re-
search Network 2011). Briefly, there were 12 genes found to be
significantlymutated in the data set. TheCT, FCPT, and LRT P-values
for these genes as well as the BMR for each mutational mechanism
category in the ovarian data set are displayed in Figure 2. BRCA1
and BRCA2 are known ovarian cancer risk genes (King et al.
2003; Pal et al. 2005). In addition to 27 (BRCA1) and 25 (BRCA2)
germline nonsense, splice site, and indel mutations, 11 and 10
nonsynonymous somatic mutations were discovered in this data
set in BRCA1 and BRCA2, respectively (The Cancer Genome Atlas
Research Network 2011).
Significantly mutated pathway/gene set analysis
To identify known cellular pathways with significant accretions of
somatic mutations in ovarian tumors, we integrated the PathScan
algorithm (Wendl et al. 2011) as a module of the MuSiC pipeline.
PathScan treats pathways as groups of genes defined by databases
such as KEGG (Kanehisa and Goto 2000), BioCarta (Nishimura
2001), and Reactome (Joshi-Tope et al. 2005), with the KEGG
definitions currently set as the default implementation. PathScan
can be configured, however, to assess any grouping of genes, including
groupings fromnonpathwaydatabases such asPfam (Finnet al. 2010).
Using PathScan, we analyzed the OV somatic mutation data
set in two ways. First, the entire data set was analyzed regardless
of the frequency ofmutation in specific genes. Secondly, due to the
overwhelming abundance ofTP53mutations,we also performed the
analysis using identical parameters but excluding TP53mutations.
The most significant pathways identified in the first analysis
were a collection of KEGG cancer pathways including ‘‘Thyroid
Cancer’’ (hsa05216), ‘‘Bladder Cancer’’ (hsa05219), ‘‘Basal Cell Car-
cinoma’’ (hsa05217), ‘‘Nonsmall Cell Lung Cancer’’ (hsa05223), and
‘‘Melanoma’’ (hsa05218). In the midst of those significant cancer
pathways sits the ‘‘p53 Signaling’’ pathway (hsa04115) at a P-value
of 2.62 3 10126. Also, MuSiC found the ‘‘Apoptosis’’ pathway
(hsa04210), including not only TP53 mutations but also nine
phosphoinositide 3-kinase mutations, to be affected. This latter
group of mutations includes two PIK3CA mutations, previously
implicated in both breast and ovarian cancers (Levine et al. 2005).
In the second analysis where TP53mutations were excluded,
the collection of KEGG cancer pathways was no longer identified
as the most significant pathways in the OV data set. Instead, for
instance, this analysis identified the environmental information
processing class ‘‘Receptors and Channels’’ pathway from the KEGG
Brite database (hsa04000) as the most significant (P = 4.363 1091)
Table 1. Analyses performed and the variants included for each
MuSiC module
MuSiC module Analysis type Variants included
SMG test Statistical test Optionala













Pfam annotation Database query All
aIn all of the tools, a user may optionally include only nonsynonymous
variants, or, alternatively, both nonsynonymous and synonymous variants
may be considered.
Figure 1. MuSiC flow diagram. MuSiC modules can either be imple-
mented individually with various required input files or may be imple-
mented in serial via one command where four inputs are used to execute
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(Table 2). Limiting the analysis scope to the KEGG Pathway data-
base, a similar pathway was identified from the environmental
information processing class, the ‘‘Neuroactive Ligand-Receptor
Interaction’’ pathway (hsa04080). This pathway incurred 266
mutations across the OV data set yielding a P-value of 2.53 1011.
The ‘‘Calcium Signaling’’ pathway (hsa04020, P = 4.9 3 108) also
rose to the level of significance from the TP53-excluded KEGG
analysis, which is interesting due to the role of calcium signaling in
many cellular processes including cell death (Crompton 2000). The
results from the OV data set feature 266 mutations throughout this
pathway, highlighted by 35mutations in voltage-dependent calcium-
channel genes (CACNA1A-H and CACNA1S), and 25 mutations in
RYR1 and RYR2 genes, whose expression
has been correlated with tumor grade in
breast cancer (Abdul et al. 2008).
Mutation relation test
The mutation relation test (MRT) at-
tempts to reveal correlations and mutual-
exclusion relationships among significantly
and highly mutated genes in a pairwise
fashion. Positive correlations suggest that
mutations and their associated pathways
putatively function synergistically to pro-
mote carcinogenesis, while negative corre-
lations imply that the alteration of a single
component or pathway may be sufficient,
wholly or in part, for carcinogenesis.
An example heat map of the MRT
analysis for all 316 OV samples is shown
in Figure 3. For this data set, we found
examples of both concurrent mutations
and also mutually excluded mutations among the genes repre-
sented in the heat map. Co-mutators FAT3 and EMR3 (P = 0.0333)
are both members of the ‘‘Receptors and Channels’’ KEGG path-
way (hsa04000), identified as significantlymutated in the pathway
analysis described above. And there is also mild evidence of the
mutual exclusion of RB1 and TP53mutations (P = 0.0141). Both of
these genes are tumor suppressors, and bothwere foundpreviously
to be significantly mutated genes in this data set (The Cancer Ge-
nome Atlas Research Network 2011). This result is potentially
meaningful if one considers the possibility that RB1 mutations
could be driver events that act independently from TP53. It is well
known that the rate of TP53 mutations in ovarian cancer is very
Figure 2. Mutation rates and SMGs in the OV data set. (A) The cohort-wide background mutation
rates for all seven mutational mechanism categories are plotted for the OV data set. The overall BMR is
also plotted, combining all types of mutations. (B)Log10(P) for the top 12 OV SMGs are plotted for all
three SMG tests in order of decreasing convolution test P-value.
Table 2. PathScan results for the OV data set









Receptors and channels hsa04000 4.36 3 1090 4.36 3 1090 3.24 3 1089 6.15 3 1088
Transcription factors hsa03000 3.14 3 1093 3.15 3 1041 2.60 3 1092 2.22 3 1039
Olfactory transduction hsa04740 2.61 3 1032 2.61 3 1032 1.47 3 1031 1.23 3 1030
Focal adhesion hsa04510 3.03 3 1029 3.03 3 1029 1.64 3 1028 1.07 3 1027
Neuroactive ligand-receptor interaction hsa04080 1.11 3 1023 1.11 3 1023 5.80 3 1023 3.13 3 1022
ECM-receptor interaction hsa04512 1.40 3 1023 1.40 3 1023 7.05 3 1023 3.29 3 1022
CAM ligands hsa04516 5.78 3 1023 5.78 3 1023 2.81 3 1022 1.16 3 1021
Cellular antigens hsa04090 1.85 3 1019 1.85 3 1019 8.70 3 1019 3.26 3 1018
Protein kinases hsa01001 1.76 3 1016 1.76 3 1016 8.01 3 1016 2.76 3 1015
Peptidases hsa01002 2.05 3 1015 2.05 3 1015 9.03 3 1015 2.89 3 1014
Cytoskeleton proteins hsa04812 1.36 3 1014 1.36 3 1014 5.81 3 1014 1.74 3 1013
Ubiquitin system hsa04121 1.60 3 1014 1.60 3 1014 6.64 3 1014 1.88 3 1013
Calcium signaling pathway hsa04020 4.24 3 1014 4.24 3 1014 1.71 3 1013 4.60 3 1013
Pathways in cancer hsa05200 3.26 3 1073 8.81 3 1014 2.19 3 1072 8.87 3 1013
Cell adhesion molecules (CAMs) hsa04514 2.02 3 1011 2.02 3 1011 7.91 3 1011 1.90 3 1010
Cytokines hsa04052 4.58 3 1011 4.58 3 1011 1.75 3 1010 4.04 3 1010
Chromosome hsa03036 6.16 3 1011 6.16 3 1011 2.29 3 1010 5.11 3 1010
Cytokine-cytokine receptor interaction hsa04060 8.46 3 1011 8.46 3 1011 3.05 3 1010 6.26 3 1010
Regulation of actin cytoskeleton hsa04810 8.79 3 1011 8.79 3 1011 3.05 3 1010 6.26 3 1010
GTP-binding proteins hsa04031 8.88 3 1011 8.88 3 1011 3.05 3 1010 6.26 3 1010
Cell adhesion molecules (CAMs) hsa04515 1.25 3 1010 1.25 3 1010 4.20 3 1010 8.39 3 1010
Tight junction hsa04530 4.26 3 1009 4.26 3 1009 1.40 3 1008 2.73 3 1008
Glycosyltransferases hsa01003 1.63 3 1008 1.63 3 1008 5.22 3 1008 9.99 3 1008
Chemokine signaling pathway hsa04062 2.38 3 1008 2.38 3 1008 7.46 3 1008 1.40 3 1007
Antigen processing and presentation hsa04612 9.47 3 1008 9.47 3 1008 2.90 3 1007 5.29 3 1007
The top 25 significantly mutated pathways as discovered using PathScan are listed here, sorted by the P-value calculated while excluding gene TP53.
MuSiC analysis tool suite
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high (Ahmed et al. 2010), including the OV data set used in this
analysis (The Cancer Genome Atlas Research Network 2011). How-
ever, for the few cases that do nothave a drivermutation in TP53, we
speculate, based on our mutual exclusion results, that mutations in
RB1 may represent an independent path to ovarian adenocarci-
noma. Of course, due to the small numbers of mutations present
in RB1 and EMR3 (six and five mutations, respectively), additional
data would be required to confirm any hypotheses generated using
these results.
Clinical correlation test
The clinical correlation test (CCT) can be used to determine re-
lationships between clinical phenotypes and observed mutations.
The input clinical data may be represented in either numeric or
categorical (‘‘class’’) formats. For example, in the OV data set, we
obtained clinical data for 315 of the 316 OV samples; the numeric
clinical data consisted of the patients’ ages at disease diagnosis and
also their survival periods (in days), and the categorical clinical
data for the OV data set included information about a sample’s
race, tumor stage, tumor grade, the outcome of the primary ther-
apy, and, lastly, their vital status. For both data types, the goal of
the CCT is to determine whether specific mutations/genes are as-
sociated with a particular clinical feature. As these associations can
sometimes be biased by covariate clinical features, MuSiC also of-
fers a generalized linear model (GLM) analysis option within the
CCT. This tool allows users to define any number of clinical traits as
covariates to discoveredmutations and, subsequently, to eliminate
any possible biases introduced to the phenotype/mutation asso-
ciations by the covariates’ effects.
As a proof of principle, we have assessed the well-established
relationship between the presence of a BRCA1 germline variant
and a patient’s age at disease diagnosis (Hall et al. 1990; Miki et al.
1994). In the OV data set, the CCT revealed that patients with
germline BRCA1 variants were significantly correlated with earlier
disease diagnosis (P = 2.456 3 105, Wilcoxon rank sum test),
whereas patients with somatic BRCA1
mutations exhibited no such correlation
(P = 0.308). A boxplot of the ages at di-
agnosis for the OV samples (Fig. 4) clearly
shows that themean age of those samples
with a germline BRCA1 mutation (51.3
yr) is lower than those samples with ei-
ther wild-type BRCA1 (60.4) or with a so-
matic BRCA1 mutation (63.1 yr). Thus,
the CCT correctly evaluated the relation-
ship between germline variants in BRCA1
and ovarian cancer susceptibility.
Proximity analysis
In certain genes, mutations tend to cluster
in close proximity within functional do-
mains. In order to find these dense ‘‘clus-
ters’’ ofmutationswithinamutation list,we
have developedMuSiC’s proximity analysis
module. Thismodule searches within fixed
windows around each mutation, reporting
the number of and distances to all neigh-
boring mutations. The size of the fixed
windows utilized for searching is user-
configurable. In order to determine an ap-
propriate default size for thesewindows,we
have analyzed the distances between all neighboring mutations in
version54of theCOSMICdatabase (seeMethods). Upon finding that
over 25% of the nearest-neighbor mutations in COSMIC are within
seven (or less) amino acids of each other, we chose to search 7 aa both
upstream of and downstream from each OV mutation for dense
clusters of variants. TP53, with 302 total nonsilent somatic muta-
tions in the OV data set, dominated the proximity analysis results.
The average number of mutations within 7 aa of another TP53
mutation was 4.9, with the densest 14-aa window containing 26
nonsynonymous mutations.
Figure 3. Mutation relation analysis. A heat map showing mutations in highly mutated genes for all
316 OV samples. Dotted-line boxes highlight concurrent nonsynonymous EMR3 and FAT3 mutations
(two concurrent mutations out of five nonsynonymous mutations from EMR3 and 18 from FAT3, P =
0.0333) and mutually exclusive nonsynonymous RB1 and TP53 mutations (297 mutually exclusive
mutations out of six nonsynonymous mutations from RB1 and 299 from TP53, P = 0.0141).
Figure 4. BRCA1 variant status versus sample age of diagnosis for theOV
data set. A boxplot of the age of diagnosis of 315 OV patients grouped by
their BRCA1 mutation status. Germline BRCA1 variant status is correlated
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The next-densest group of mutations occurred in DNAH5,
where there were four mutations within a space of 3 aa. Several
genes have mutations that occur in triplets within a space of 2 aa,
including UBR4 and RB1CC1. Both UBR4 and RB1CC1 have re-
lationships with RB1, a gene on the significantly mutated gene list
for the OV data set and a gene also found to harbor copy-number
alterations in the OV data set (The Cancer Genome Atlas Research
Network 2011). UBR4 is a component of the N-end rule pathway
that interacts with RB1, and RB1CC1 actually regulates the expres-
sion of RB1. RB1 itself has twomutations in close proximity (within
1 aa of each other). These high-density groups of RB1-related mu-
tations, pictured in Figure 5, may support the hypothesis that RB1
could be an additional driver of ovarian cancer.
COSMIC/OMIM query
Using theCOSMIC/OMIMmodule ofMuSiC,we attempted to find
previously reported mutations matching the query set of somatic
OV mutations. This type of analysis can provide a measure of re-
currence, as these databases generally contain information about
the studies fromwhich their contentswere derived, and theCOSMIC
database deals exclusively with the somatic mutations discov-
ered in cancer studies. A summary of COSMIC/OMIM database
comparisons for those significantly mutated genes listed above
with at least one database match of any type is presented in Sup-
plemental Figure S2. This summary, however, represents only
a subset of all of the information made available via the database
queries. We found 15 exact matches in genomic position and nu-
cleotide change between the OV data set and COSMIC, including
sites inNF1, RB1, and PIK3CA, all considered significantlymutated
genes by the MuSiC pipeline. This type of match is only possible
when comparing to the COSMIC database, since OMIM entries
contain only amino acid coordinates. We identified another exact
match in the FOXG1 gene, which encodes a forkhead transcription
factor. Not only was the FOXM1 transcription factor network cited
as significantly altered in 87% of samples in the previous TCGA
study (The Cancer Genome Atlas Research Network 2011), but,
additionally, some forkhead transcription factors were previously
identified as therapeutic targets (Moumne et al. 2008; Wang et al.
2010b).
In addition to finding the above COSMIC variants which
shared positions and identical nucleotide changes with OV mu-
tations, our comparison of OV mutations to the COSMIC and
OMIM databases also identified a large set of database mutations
that altered the same amino acid in an identical manner as an OV
mutation. Of 233 such matches from COSMIC (76 from OMIM),
the overwhelming majority of these, 219
(56), were from the gene TP53. There
were 229 (76) other ‘‘position’’ matches,
defined as mutations which affect an iden-
tically positioned amino acid but which
do not cause the same residue change as
the previously reported mutation. Most
of thesematches are from genes that have
been previously associated with ovarian
cancer (TheCancerGenomeAtlas Research
Network 2011), such as BRAF, BRCA1,
KRAS, and again, TP53.
Pfam annotation
The Pfam annotation module of MuSiC
groups genes based on the frequency of
mutation in specific protein domains.
Grouping mutations by their protein do-
main can serve to group genes according
to putative function, since genes that share
a domain are more likely to share related
functions.We performed Pfam annotation
on the 19,356 somatic variants identified
in the 316 OV cases. Supplemental Table
S1 reports the number of nonsynonymous
mutations, synonymous mutations, and
also the number of genes harboring mu-
tations in each Pfam domain with at least
five somatic events in the OV data set.
In the analysis of the OV data, many
of the frequently mutated domains are also
themost prevalentdomains in thegenome,
including the seven-transmembrane G
protein-coupled receptor domain, the pro-
tein kinase domain, and the zinc finger
domain, as illustrated in Figure 6A. This
genome-wide abundance is not true, how-
ever, for the amply mutated P53 domain.
Figure 5. Proximity analysis mutation diagrams. These mutation diagrams show recurrent triplet
mutations in both UBR4 and RB1CC1, both of which harbor a relationship with tumor suppressor gene
RB1.
MuSiC analysis tool suite
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Analysis of this Pfam annotation result correctly confirms the
significance of the P53 domainmutations in this cohort. Figure 6A
also shows that this domain is recurrently mutated but only in
a small number of genes, much different from all of the other
domains pictured. And lastly, Figure 6B shows that the P53 domain
has an unusually high nonsynonymous:synonymous mutation
ratio. All of these details are indicative (correctly) of an important
mutation hotspot in this cohort.
The Pfam annotation module output may also be modified
slightly and fed into the SMG test algorithm in order to produce
a mathematical result describing ‘‘significantly mutated domains’’
(rather than significantly mutated genes) and their associated
P-values. For a detailed explanation of this option, please see the
Supplemental Material, including Supplemental Table S2. The re-
sults presented therein reaffirm the significance of the mutations
in the P53 domain, as well as in the other frequently mutated
domains.
Discussion
There are several software tools available purporting to determine
mutational significance. CHASM (Carter et al. 2010), for instance,
uses amachine-learning technique to distinguish drivermutations
frompassengers based on a driver/passengermutation training set.
Mutation Assessor (Reva et al. 2011) provides a prediction of the
functional impact of a mutation based on the specificity of mul-
tiple sequence alignments and conservation scores. And tools such
as CanPredict (Kaminker et al. 2007) are database-driven, deriving
multiple metrics for each variant, starting with stored information
and models, and then making use of the metrics through a de-
cision-tree analysis. Other tools, such as ANNOVAR (Wang et al.
2010a), provide detailed annotations of genetic alterations,much
like MuSiC’s Pfam annotation module. Although not currently
publicly available, the ‘‘Firehose’’ pipeline does share some fea-
tures with MuSiC, including an SMG analysis tool and a pathway
analysis tool, PARADIGM (Vaske et al. 2010), but Firehose as a
whole is heavily focused onorderly sequencing andquality control
rather than post-discovery variant analysis.
MuSiC, on the other hand, is the first available set of com-
bined tools that enables a complete, multidimensional statistical
evaluation of next-generation-derived cancer data sets. No other
publicly available tool suite currently incorporates clinical data
along with coverage data and database references into the
determination of the most significant
mutations among a large mutation list full
of passengers. MuSiC merges several meth-
odological aspects of the above-mentioned
tools with many novel additional algo-
rithms, providing the capability of large-
cohort, data-driven statistical analysis to
the entire research community.
Use ofMuSiC is straightforward. The
simplicity of the input files and tool
updating make this package extremely
accessible.MuSiC also accommodates both
large and small research organizations;
although the entire suite of tools is capa-
ble of running sequentially on a single
processor, the most CPU-intensive mod-
ules offer easily parsable options for par-
allelizing jobs across multiple machines
or across a job cluster.
Future support for the MuSiC package will be devoted to the
handling of additional file formats, such as the variant call format
(VCF), and also to the development of a graphical user interface
(GUI). We intend to design new tools aimed at incorporating
a wider variety of biological and variant data types, such as copy
alteration data, and 3Dprotein structures fromRCSB’s ProteinData
Bank (Berman et al. 2000), to be used for improved proximity
analysis calculations. We also intend to implement recurrence
tests across other data entities, such as significantly mutated
transcripts and significantlymutated gene families.We also plan
to enhance the assessment of the functional impact of pro-
tein mutations in MuSiC through the integration of published
solutions, such as Mutation Assessor (Reva et al. 2011) and
PolyPhen-2 (Adzhubei et al. 2010), as well as through the design
of new modules which take advantage of databases that cate-
gorize such effects, such as SIFT (Kumar et al. 2009). And lastly, a
fuller integration of the results from various MuSiC modules,
many of which are currently considered in isolation, will provide an
even more comprehensive picture of cancer genomic mechanisms.
Methods
Sample data set used in this study
Alignment mapping files for the ovarian cancer cohort, as well as
all mutational data in mutation annotation format (MAF) are
available at The Cancer Genome Atlas (TCGA) website, http://
cancergenome.nih.gov/, via dbGaP. The dbGaP study accession
number is phs000178.v1.p1.
Significantly mutated gene tests
We describe our calculation of background mutation rates and
three methods for calculating summarized P-values below.
Background mutation rate (BMR)
Calculations of BMR, although simply described as the number of
mutated bases per total bases, are often controversial. Our method
is dependent upon the data available, under the premise that the
number of bases having available alignment data should provide
the denominator for the BMR calculation, since this number also
provides the upper limit to the number of bases available for mu-
tation discovery. Therefore, we first count the number of bases
with sufficient aligned read-depth based upon user-defined coverage
Figure 6. Pfam domains affected by OV mutations. (A) A histogram of the most highly mutated
domains in the OV data set next to the number of genes affected in each domain. (B) A stacked bar-
graph where the value 100% represents the total number of mutations in a particular Pfam domain.
Lighter and darker sections of the bars represent which proportions of the total mutations are non-
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limits set independently for the tumor andnormal BAMfiles for each
sample in the cohort. For the purposes of our algorithm, counts are
determined for six specific reference sequence-baseddenominations,
with separate counts for eachofA andTbases, CpG-connectedCand
G bases, and lastly C and G bases not connected as CpG. We also
categorize the discovered mutations along the lines of mutational
mechanism, with separate categories for AT transitions, AT trans-
versions, CpG transitions, CpG transversions, CG (non-CpG) tran-
sitions and transversions, and a seventh ‘‘indel’’ category, for which
we use the entirety of the covered space in the sample-set when
comparing indel-affected bases versus available bases. In order to
calculate the BMR of each mutational mechanism category, the
number of mutations found in that category is divided by the
total number of bases available in which such a call could have
been made.
MuSiC allows for the calculation of BMR and for the sub-
sequent comparisons of mutation rate to BMR, to be performed
separately for each subgroup in a user-specified number of sub-
groups. If the user specifies that only one subgroup is to be con-
sidered (the default option), then the entire cohort is used in the
calculations of mutation rate and BMR for the seven mutational
mechanism categories. In this case, seven P-values are generated
for each gene and are summarized using the three methods de-
scribed below. However, if more than one subgroup is to be con-
sidered for a given cohort, the mutation rates and BMRs for the
seven mutational mechanism categories are calculated separately
for each subgroup (seven mutation rate and BMR calculations per
subgroup), with P-values generated for each category within each
subgroup. In this case, the number of P-values generated for each
gene will equal seven times the number of subgroups to be con-
sidered. All P-values for each gene are still summarized using the
three methods discussed below.
If the number of subgroups to be considered is greater than one
but not equal to the number of samples in the cohort, the BMR for
each sample is first calculated individually, and then these per-
sample BMR values are clustered using k-means clustering into the
number of subgroups specified by the user. These clustered sub-
groups are then used for all subsequent mutation rate and BMR
calculations. Alternatively, if the number of subgroups specified by
the user equals the number of samples in the cohort, then each
sample is considered independently for eachmutation rate and BMR
measurement.
The BMRs calculated across the entire OV data set for each
mutational mechanism category, including the overall BMR across
all categories, are plotted in Figure 2A.
Fisher’s combined P-value test (FCPT)
FCPT combines all P-values for a particular gene into a statistic, xc,
according to Fisher’s method (Fisher 1925),




where pi is the P-value obtained via binomial distribution for the
i-th subgroup mutational mechanism type, and k the number of
subgroup mutational mechanism categories for a gene. The final
P-value for the entire gene is calculated as the probability of
observing a value no less than xc, based on a x
2 distributionwith 2k
degrees of freedom.
Likelihood ratio test (LRT)









where Mi, Ci, Ri, and ri are mutation number, coverage, BMR, and
maximum likelihood estimate (MLE) of the mutation rate, re-
spectively, for the i-th subgroup mutational mechanism category
of a gene, k is the number of mutation types, and L() is the like-
lihood of observed mutation number for the i-th subgroup muta-
tional mechanism category, defined as the point probability of
observing Mi mutations given a coverage of Ci and a mutation
rate of Ri or ri. The final P-value for the entire gene is calculated as
the probability of observing a value no less than xl, based on an
approximate x2 distribution with k degrees of freedom.
Convolution test (CT)
CT calculates a summarized log statistic of joint binomial point
probability,




whereMi, Ci, Ri, k, and L() are referred to as the same as in the LRT
method. Getz et al. (2007) proposed that the P-value for a gene can
be calculated by taking one minus a left-tail probability, i.e., the
probability of observing a value less than Sg, and the semiexact
distribution of Sg can be obtained by a binned histogram-based
convolution procedure. This procedure is advantageous for the
large amounts of data involved in genome-wide investigation of
cohortmutations because it provides exact P-values in aminimum
amount of computation time; usually one must choose between
precision and length of compute. However, one disadvantage of
this convolution procedure is that the two tails of the Sg distribu-
tion are mixed, and therefore the directionality is lost. In this case,
both improbably large mutation rates and improbably low muta-
tion rates give high values for Sg. To remedy this issue, our CT
method modifies the published convolution procedure by ex-
cluding genes with mutation rates that are close to or equal to 0.
In other words, we exclude genes whose mutation rates are ex-
tremely far below the BMR, as they never would be considered
‘‘significantly mutated’’ in practice.
The output file for the SMG test is a compilation of the
P-values for each test for each gene under the null hypothesis that
the number of mutations seen in the gene is in accordance with
those seen in the background. False discovery rates are also
reported for each test for each gene.
Significantly mutated pathway/gene set analysis
Sequence data froma single cancer genomedonot contain sufficient
information to adequately investigate pathway/phenotype associa-
tions. This problem requires systematic analysis of larger cohorts.
There are several published methods for identifying significantly
mutated pathways or gene sets (e.g., Lin et al. 2007; Tarca et al. 2009;
Vaske et al. 2010), but we have incorporated a new tool called
PathScan into the MuSiC package. PathScan accounts for two
important factors other methods neglect: (1) variations in gene
lengths and the consequent differences of their mutational likeli-
hoods under the null hypothesis; and (2) distribution ofmutations
among samples and their proper combination into an overall
P-value.
We have configured PathScan in MuSiC to perform pathway
analysis using a wide variety of annotated databases, including
KEGG (Kanehisa and Goto 2000), BioCarta (Nishimura 2001), and
Reactome (Joshi-Tope et al. 2005), as mentioned above. The results
described abovewhereTP53 is excluded from the pathway analysis
are achieved easily through MuSiC’s implementation of a parame-
ter called ‘‘genes-to-ignore,’’ in which the user may provide
a comma-delimited list of geneswhosemutations should be skipped
over when reading the MAF file during the analysis.
MuSiC analysis tool suite
Genome Research 1595
www.genome.org
 Cold Spring Harbor Laboratory Press on November 13, 2013 - Published by genome.cshlp.orgDownloaded from 
Mutation relation test (MRT)
We have developed the MRT to look for any latent relationships
among mutated genes. This module is a correlation test for two
binary variables to see whether or not any two genes are mutated
concurrently (positive correlation) or exclusively (negative corre-
lation). Because the numbers of mutated genes may vary signifi-
cantly among samples (most have only a few mutations whereas
some may have many), and because direct correlation between
genes in high-mutation-count samples is not comparable to that in
low-mutation-count samples, classic correlation analysis is invalid.
To control for this confounder, we calculate P-values in the MRT
through a restricted permutation, taking into account the distri-
bution of mutated gene numbers amongt the samples. Permuta-
tions are performed, therefore, by first calculating the numbers of
mutated genes in individual samples and then randomly per-
muting the observed mutations, keeping both the number of
mutations in each gene and also the distribution of mutated gene
number per sample constant. Concurrence and exclusion among
mutations are tested separately. This method has been successfully
applied to lung cancer data in our previous study (Ding et al. 2008).
Clinical correlation test (CCT)
TheCCTmodulewas developed for detecting correlations between
mutations and clinical features. Mutation data are again treated as
0-1 variables, where all mutations occurring within the same gene
are grouped (the default method), or optionally, where a more
strict definition of collapsing is used, grouping only those muta-
tions with identical genomic coordinates and nucleotide changes.
Clinical features can either be categorical or numerical variables,
where a Fisher’s exact test (and optionally, a x2 test) is used to
calculate P-values for categorical clinical data, and aWilcoxon rank
sum test (and optionally, Pearson’s correlation) is used to analyze
numerical clinical data. The null model for the calculated P-values
depends on the type of clinical data being analyzed. For categorical
clinical data, the nullmodel is thatmutations happen randomly in
the various categories represented across the samples, with no
preference given to any one category. For numerical clinical data,
the null model is thatmutations have no effects on a trait (i.e., that
mutations will not increase or decrease the value of the numeri-
cally reported trait).
A GLM analysis option also exists in which a user may define
an analysis model which must include a response variable and
a variant, and then any number of covariates may be considered.
The variants and covariates may all be clinical features, or, more
typically, genes from the mutation list should be listed as variants,
with clinical features making up the covariates. The output of the
GLM option includes a P-value which indicates association be-
tween the response variable and the variant, as well as other
standard outputs from a deviance analysis.
Proximity analysis
In MuSiC, we have defined proximity analysis as an investigation
of the density of mutations across a cohort in the amino acid space
of a given gene’s annotated transcript. The goal of this analysis is to
extract evidence of mutations clustered within specific domains,
an eventwhich is significant in light of the nullmodel where point
mutations occur at random locations throughout the genome.
Highly mutated domains across a group of samples might be in-
dicative of an underlying mechanistic association which contrib-
utes to the shared condition of the cohort, such as the onset of
disease. The specific action taken in the tool is to query the dis-
tance (in number of amino acids) between every pair of mutations
on a given transcript of a mutated gene within the sample set, and
then to determine which mutations fall within ‘‘close proximity.’’
‘‘Close proximity’’ may be determined by the user as an input to
the module, with the units of this parameter being the number of
sequential amino acids between two events.
The algorithm operates as follows: First, the amino acid po-
sition of each mutation within its respective transcript is de-
termined. Then, for each mutation in the input MAF file, two
values are calculated: (1) the number of other mutations on the
same transcript within the proximity limit set by the user; and (2)
the distance to the closest other mutation in this nearby set. (Note
that if more than one mutation occurs within the same amino
acid, the distance to the closest mutation in this case would be
0 aa.) Then, for eachmutation, we report a few general details from
the MAF file in the output, such as the genomic coordinates, ref-
erence and variant bases, and the sample in which the mutation
was found. We further report the calculated values, such as the
amino acid position of themutationwithin the transcript, and also
(1) and (2) listed directly above.
In the Proximity Analysis Results section, we chose to use 7 aa
as the maximum distance from any OVmutation within which to
look for clusters of mutations. This default distance was chosen
after querying the entire COSMIC mutation database (version 54,
comprising 171,473 mutations), and looking for the proximity of
mutations found in dense clusters. For each gene present in the
database, we calculated the distance between each mutation in
that gene and its closest neighboring mutation. As many muta-
tions sharing the exact same genomic coordinates are reported
more than once in COSMIC, we only used one instance of each
mutational position when calculating nearest-neighbor distances.
Through these per-genemeasurements, we found that over 25% of
all neighboringmutations inCOSMICarewithin 7 aa of each other
(25% thus represents the first quartile of nearest-neighbor dis-
tances). We thus set 7 aa as the default range within which to
search for clusters of mutations in the proximity analysis module.
COSMIC/OMIM query
In the COSMIC/OMIM tool, a list of mutations is queried for re-
currence against both the Catalogue of Somatic Mutations in
Cancer (COSMIC) database and theOnlineMendelian Inheritance
in Man database (OMIM). The usefulness of this tool is twofold;
first, recurrent events between these two databases and a list of
variations froma cohort provide a quick extension set, especially as
the databases are expanded over time, and secondly, we have
downloaded entries from the COSMIC database related to muta-
tions that report some type of amino acid transformation and
provide this filewith theMuSiCpackage,making this type of query
very user-friendly.
The tool functions as follows: For everymutation found in the
input MAF file, information related to this mutation is gathered
from both the COSMIC and OMIM databases. Relevant in-
formation is ascertained by relating the genomic coordinate
(COSMIC) or the amino acid change (COSMIC and OMIM) asso-
ciated with the variant to all database entries. (Note that the MAF
used as inputmust contain an additional field with columnheader
‘‘amino_acid_change,’’ which is the field searched for to perform
the amino acid comparison.) A database entry must lie within the
user-specifiednumber of bases (default = 5) or amino acids (default =
2) of the MAF variant to be considered as a ‘‘nearby’’ match. We
view the thresholds for ‘‘nearby’’ matches as adequate for taking
into account the different definitions of reference sequences and
gene transcripts that may be used by different contributors to the
databases. Alternatively, ‘‘exact’’ matches are direct overlaps in both
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and a mutation found in the database. If only the location (the
genomic coordinate or amino acid position) of a variant match
a database entry but not the nucleotide or amino acid change, these
matches are deemed ‘‘position’’ matches. We currently ignore silent
mutations in OMIM queries, as these types of mutations do not
affect protein coding.However, the positions of silentmutations are
still considered in comparison with the COSMIC database.
All discoveries based on these database queries are appended
to the input MAF file as extra columns (one column per database).
The information written to the output file by the tool will either
describe ‘‘exact’’ or ‘‘position’’matches in amino acid or base change
or will (optionally) give all results from the gene associated with
the variant for a ‘‘nearby’’ match, one of which must qualify the
site as actually having a ‘‘nearby’’ match. If a variant has nomatch
in the particular database, a ‘‘novel’’ declaration is made for the
variant, and (again, optionally) all of the results found from the
associated gene will be printed next to the declaration to give
the user an idea of what matches are possible for that gene. And
lastly, if the gene for a variant is not found in the database, amessage
noting this circumstance is printed along with a ‘‘novel’’ declaration
for the variant.
For each queried database, the tool further prints an output
summary which tallies the types of matches found throughout the
entire data set using that database. The user can learn, for instance,
how many sites matched exactly in both nucleotide and position,
or perhaps how many variants matched database entries in only
the amino acid category (labeled AA in the summary) while not
matching in exact position or nucleotide change (labeled NT).
Pfam annotation
Our Pfam annotation tool supposes the use of Sanger’s Pfam da-
tabase (cited above) as another avenue for defining recurrence
within the mutation list of a large group of cancer samples. The
Pfamdatabase is a catalog of functional regions (or domains) present
within protein sequences. Referencing this list with the locations of
somatic mutations across a cohort provides knowledge about which
domains are most frequently affected by mutations in a certain dis-
ease and, therefore, may provide some insight as to the significance
(or insignificance) of the mutations in question.
In order to use the Pfam database, we have translated the
catalog’s amino acid coordinate system into a genomic position
coordinate system. The amino acid sequences chosen to be trans-
lated were ranked at every coding and splice site position in the
genome, based first on the translational and functional effect
predicted by the transcript at a given position, and then secondly
on the NCBI status of the particular transcript. The sequence of the
‘‘best’’ transcript chosen at each site was used to recover Pfam do-
mains fromSanger’s database.Wehave incorporated this information
into a table used by the tool via a fast-lookup program called Tabix,
available in the SAMtools package (Li et al. 2009). The Pfam anno-
tation module uses the genetic coordinates of a variant to append
a Pfam annotation domain column to the end of any MAF file.
This tool has been expanded to query a few other protein
annotation databases in addition to Pfam.We provide information
from the SUPERFAMILY database (Wilson et al. 2009), the SMART
database (Schultz et al. 2000), and the Patternscan database in our
annotation query. (Patternscan is a new version of the Prosite
database [Sigrist et al. 2010].) Patternscan provides information
similar to that of the Pfamdatabase regarding protein domains and
families at functional sites, but SUPERFAMILYand SMART focus on
evolved protein structural families and signaling protein domains,
respectively. All of this information will be present in the output
file, comma delimited, with the name of the database separated
from the annotation result by an underscore.
Software availability
The MuSiC software tools, source code, and reference data are ac-
cessible through our website, http://gmt.genome.wustl.edu, and
are supported on Ubuntu Linux 10.04 (Lucid Lynx). Installation
on all Debian-based systems will initiate automatic updates from
our software server. The MuSiC suite is also available on CPAN
(http://www.cpan.org) and GitHub (https://github.com) under the
namespace ‘‘Genome’’ in both locations, and integration of MuSiC
into Galaxy (http://usegalaxy.org) is also available. A summary of
benchmarking statistics for each MuSiC module is available in the
Supplemental Material.
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